ImCheck Therapeutics ICT01 drug candidate is still under investigation for its safety and efficacy, therefore its use and access is restricted to clinical trials at this time.
Questions and requests from physicians regarding early access can be made through this e-mail address GlobalMedInfo(at)ipsen(dot)com
(1) Other terms commonly used: Compassionate Use, Early Access, Expanded Access Program, Managed Access Program, Patient Access Program, Special Access Program, Scheme Access Program, Temporary Use Authorization and Pre-approval access.